Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy; Analysts Reiterate Buy Ratings
An incredible amount of planning and preparation goes into the design of…
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity…
